Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)

PHASE2CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

May 13, 2016

Study Completion Date

June 17, 2019

Conditions
Advanced Chemorefractory Colorectal Adenocarcinoma
Interventions
DRUG

regorafenib

Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.

Trial Locations (17)

1000

Jules Bordet Institute, Brussels

1070

Hopital Erasme, Brussels

1340

Clinique Saint Pierre, Ottignies

2300

AZ Turnhout, Turnhout

2650

UZA, Antwerp

4000

Centre Hospitalier Universitaire de Liège, Liège

Clinique St Joseph, Liège

5000

Centre Hospitalier Régional de Namur, Namur

Clinique et Maternité Sainte Elisabeth, Namur

5530

Cliniques Universitaires UCL de Mont-Godinne, Yvoir

6000

Grand Hopital de Charleroi, Charleroi

6540

Centre hospitalier de Jolimont, Lobbes

7000

CHU Ambroise Paré, Mons

8500

AZ groeninge, Kortrijk

8800

Hartziekenhuis Roeselare-Menen (HHRM), Roeselare

Unknown

Cliniques Universitaires Saint Luc, Brussels

UZ Ghent, Ghent

Sponsors
All Listed Sponsors
lead

Jules Bordet Institute

OTHER